Candel Therapeutics to Present Two Posters at SITC 2026

On October 2, 2026, Candel Therapeutics announced two accepted poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, scheduled for November 4–8 in Phoenix, Arizona.

The November 6 poster (abstract 603) will discuss multi-omics findings on aglatimagene besadenovec plus valacyclovir in non-small cell lung cancer progressing after immune checkpoint inhibitor treatment. Caroline Duault of Stanford University is the presenter.

The November 7 poster (abstract 468) will cover combining linoserpaturev with VEGF blockade to address hypoxia-associated immune suppression in recurrent glioblastoma. Candel Chief Scientific Officer Francesca Barone will present.

Both posters are scheduled at the Phoenix Convention Center. The announcement describes planned scientific presentations; it does not report new outcome data in the release.